Stock 2171 CARSGEN THERAPEUTICS HOLDINGS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

CARsgen Therapeutics Holdings Limited Stock

Equities

2171

KYG1996C1006

Biotechnology & Medical Research

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:49 2024-05-06 am EDT 		5-day change 1st Jan Change
5.73 HKD -7.43% Intraday chart for CARsgen Therapeutics Holdings Limited +2.32% -11.85%
Apr. 30 CARsgen Therapeutics Holdings Limited Announces Abstracts from the Ongoing Studies of zevorcabtagene autoleucel and CT071 to be Presented as an Oral Presentation and a Poster Presentation, Respectively, at the Upcoming EHA 2024 CI
Apr. 29 CARsgen Therapeutics Holdings Limited Announces Board and Committee Changes CI
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site

Financials

Sales 2024 * 330M 45.84M 358M Sales 2025 * 484M 67.13M 525M Capitalization 3.06B 424M 3.31B
Net income 2024 * -680M -94.37M -738M Net income 2025 * -708M -98.26M -768M EV / Sales 2024 * 6.3 x
Net cash position 2024 * 976M 135M 1.06B Net cash position 2025 * 297M 41.25M 322M EV / Sales 2025 * 5.7 x
P/E ratio 2024 *
-4.76 x
P/E ratio 2025 *
-4.57 x
Employees 516
Yield 2024 *
-
Yield 2025 *
-
Free-Float 58.71%
More Fundamentals * Assessed data

Chart CARsgen Therapeutics Holdings Limited

Dynamic Chart

Latest news about CARsgen Therapeutics Holdings Limited

CARsgen Therapeutics Holdings Limited Announces Abstracts from the Ongoing Studies of zevorcabtagene autoleucel and CT071 to be Presented as an Oral Presentation and a Poster Presentation, Respectively, at the Upcoming EHA 2024 CI
CARsgen Therapeutics Holdings Limited Announces Board and Committee Changes CI
CARsgen Therapeutics Holdings Limited Submits Responses to FDA Observations CI
Carsgen Therapeutics To Give Cancer Drug Oral Presentation at ASCO 2024 MT
CARsgen Therapeutics Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
CARsgen Therapeutics’ New Drug Application for Multiple Myeloma Drug Gets Approval from Chinese Regulator MT
National Medical Products Administration of China Approves New Drug Application of CARsgen Therapeutics Holdings Limited for Zevorcabtagene Autoleucel CI
CARsgen Presents Data from Phase 1B Study on Gastric, Gastroesophageal Junction Cancer Drug at US Meet MT
Carsgen Therapeutics Holdings Limited Announces Updated Clinical Research Results on CT041 at 2024 ASCO GI Meeting CI
China Grants CARsgen Clinical Trial Clearance for Liver Cancer Treatment; Shares Rise 3% MT
CARsgen Therapeutics Holdings Limited Announces CT011 Achieve Investigational New Drug Clearance from the National Medical Products Administration CI
CARsgen Therapeutics Holdings Shareholder Plans Stake Boost; Shares Fall 6% MT
US FDA Puts CARsgen's Three Drug Candidates Under Clinical Hold Following Factory Inspections; Shares Plummet 27% MT
CARsgen Therapeutics Presents Anti-Cancer Drug Data at American Conference MT
CARsgen Therapeutics Holdings Presents Results of Study for Myeloma Treatment MT
More news

Analyst Recommendations on CARsgen Therapeutics Holdings Limited

CARsgen's Myeloma Treatment Shows 100% Objective Response Rate in Phase 2 Trial; Shares Fall 4% MT
UBS Adjusts CARsgen Therapeutics' Price Target to HK$34.50 From HK$38, Keeps at Buy MT
UBS Adjusts CARsgen Therapeutics' Price Target to HK$38 From HK$53, Keeps at Buy MT
More recommendations

Press releases CARsgen Therapeutics Holdings Limited

CARsgen Submitted Responses to FDA Observations AQ
NMPA Approves the NDA for CARsgen's BCMA CAR-T Therapy Zevorcabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma AQ
CARsgen's CT011 achieves IND clearance from the NMPA for the GPC3-positive stage a hepatocellular carcinoma at high risk of recurrence after surgical resection AQ
CARsgen's CT071 Received IND Clearance from the FDA for Treating Relapsed, Refractory Multiple Myeloma or Relapsed, Refractory Primary Plasma Cell Leukemia AQ
CARsgen Announces Formation of its Clinical Advisory Board AQ
More press releases

Quotes and Performance

1 day-7.43%
1 week+2.32%
Current month-3.54%
1 month-4.18%
3 months+30.82%
6 months-49.29%
Current year-11.85%
More quotes

Highs and lows

1 week
5.49
Extreme 5.49
6.49
1 month
4.30
Extreme 4.3
6.49
Current year
3.73
Extreme 3.73
7.53
1 year
3.73
Extreme 3.73
12.64
3 years
3.73
Extreme 3.73
57.25
5 years
3.73
Extreme 3.73
57.25
10 years
3.73
Extreme 3.73
57.25
More quotes

Managers and Directors - CARsgen Therapeutics Holdings Limited

Managers TitleAgeSince
Hua Mao Wang FOU
 Founder 48 18-02-08
Zong Hai Li CEO
 Chief Executive Officer 51 18-02-08
Lan Xie DFI
 Director of Finance/CFO 52 21-02-28
Members of the board TitleAgeSince
Zong Hai Li CEO
 Chief Executive Officer 51 18-02-08
Hua Mao Wang FOU
 Founder 48 18-02-08
Xiang Ke Zhao BRD
 Director/Board Member 38 23-07-03
More insiders

ETFs positioned on CARsgen Therapeutics Holdings Limited

Name Weight AuM 1st Jan change Investor Rating
LONCAR CHINA BIOPHARMA ETF - DISTRIBUTING - USD ETF Loncar China BioPharma ETF - Distributing - USD
1.19% 4 M€ -27.92%
BMO MSCI GENOMIC INNOVATION INDEX ETF - CAD ETF BMO MSCI Genomic Innovation Index ETF - CAD
0.03% 2 M€ -.--%
UNLIMITED HFND MULTI-STRATEGY RETURN TRACKER ETF - USD ETF Unlimited HFND Multi-Strategy Return Tracker ETF - USD
0.00% 34 M€ +3.25% -
More ETFs positioned on CARsgen Therapeutics Holdings Limited

Quotes

Date Price Change Volume
24-05-06 5.73 -7.43% 1 302 500
24-05-03 6.19 -0.80% 490,000
24-05-02 6.24 +5.05% 325,000
24-04-30 5.94 +6.07% 2,010,500
24-04-29 5.6 +2.75% 1,512,300

Delayed Quote Hong Kong S.E., May 06, 2024 at 04:08 am EDT

More quotes

Company Profile

CARsgen Therapeutics Holdings Ltd is a China-based investment holding company principally engaged in discovering, developing and commercializing innovative chimeric antigen receptor (CAR)-T cell therapies. The Company’s therapies are applied in the treatment of hematological malignancies and solid tumors. The Company have developed an upgraded B cell maturation antigen (BCMA) targeted CAR-T product, CT053, which is its sole core product candidate. The Company conducts its businesses in China and the United States.
Sector
Biotechnology & Medical Research
Calendar
2024-08-19 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
2
Last Close Price
5.735 CNY
Average target price
6.662 CNY
Spread / Average Target
+16.17%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
CARSGEN THERAPEUTICS HOLDINGS LIMITED Stock CARsgen Therapeutics Holdings Limited
-11.85% 456M
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+8.64% 105B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-0.90% 104B
ARGENX SE Stock argenx SE
+5.44% 22.94B
BIONTECH SE Stock BioNTech SE
-12.25% 22.34B
GENMAB A/S Stock Genmab A/S
-6.31% 19.25B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-39.98% 17.08B
BEIGENE, LTD. Stock BeiGene, Ltd.
-8.69% 16.96B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+7.59% 14.16B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+38.96% 12.63B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 2171 Stock
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW